BusinessAchillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical ProgramsBy Nasdaq OMXNov 3, 2016, 1:00 PM UTC
BusinessAchillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCVBy Nasdaq OMXSep 23, 2016, 3:50 PM UTC
BusinessAchillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCVBy Nasdaq OMXSep 9, 2016, 10:15 AM UTC
BusinessAchillion to Present at Two Upcoming Investor ConferencesBy Nasdaq OMXSep 1, 2016, 10:05 AM UTC
BusinessAchillion to Present at the 2016 Wedbush PacGrow Healthcare ConferenceBy Nasdaq OMXAug 9, 2016, 10:05 AM UTC
BusinessAchillion to Present at Two Upcoming Investor ConferencesBy Nasdaq OMXMar 3, 2016, 11:05 AM UTC
BusinessAchillion Reports 2015 Fourth Quarter and Year-End Financial ResultsBy Nasdaq OMXFeb 25, 2016, 11:05 AM UTC
BusinessAchillion to Present at the Leerink Partners 5th Annual Global Healthcare ConferenceBy Nasdaq OMXFeb 8, 2016, 9:05 PM UTC
